NCT03219762

Study of Nab-paclitaxel in Sensitive and Refractory Relapsed SCLC

Phase II Study of Nab-paclitaxel in Sensitive and Refractory Relapsed Small Cell Lung Cancer (Nabster Study)

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 65 (estimated)
• Sponsor: Gruppo Oncologico Italiano di Ricerca Clinica · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Evaluate the activity and safety of Nab-paclitaxel in patients with sensitive or refractory SCLC who relapsed after cisplatin or carboplatin and etoposide first-line chemotherapy.

Detailed description

Phase II study of NAB-paclitaxel in SensiTivE and Refractory relapsed SCLC

Conditions

• Small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Nabpaclitaxel	Chemotherapy will be continued until a maximum of 6 courses or progressive disease or intolerable toxicity or patient refusal. In patients with confirmed and prolonged disease response, clinical benefit and good tolerance to study drug treatment, the investigators can evaluate to continue therapy beyond 6th cycle, after discussion with Principal Investigator (PI) of the study

Timeline

• Start date: 2017-02-07
• Primary completion: 2019-01-01
• Completion: 2019-01-01
• First posted: 2017-07-18
• Last updated: 2017-07-26

Locations

26 sites across 1 country: Italy

Regulatory

• FDA-regulated drug study